Author(s)

Daouda Ouédraogo¹, Grissoum Tarnagda², Jean Claude Romaric Pingdwindé Ouédraogo², Amed Héma¹, Simon Tiendrebéogo², Salfo Ouédraogo², Geoffroy Gueswindé Ouédraogo², Lazare Belemnaba², Noufou Ouédraogo², Félix Dit Bondo Kini², Zékiba Tarnagda², Martial Ouédraogo^1*, Sylvin Ouédraogo²

¹Service de Pneumologie/Centre Hospitalier Universitaire Yalgado Ouédraogo (CHU-YO), Ouagadougou, Burkina Faso.
²Institut de Recherche en Sciences de la Santé/Centre National de la Recherche Scientifique et Technologique (IRSS/CNRST), Ouaga-dougou, Burkina Faso.

Background: Since the appearance of the COVID-19 pandemic, several drugs have also been proposed for the treatment of the COVID-19, but the therapeutic effectiveness of those drugs is not satisfactory. This situation has led to the search for therapeutic solutions based on recipes from traditional medicine. Aims: This study aimed to evaluate the clinical safety, efficacy and tolerability of the phytomedicine APIVIRINE in patients with non-severe COVID-19. Methods: Patients were included following defined criteria and followed on an outpatient basis until recovery in accordance with national guidelines for the management of single cases of COVID-19 in Burkina Faso. Vital signs, anthropometric parameters as well as electrocardiographic, hematological and biochemical examinations were measured on D4, D7, D14 and D21. Adverse events were recorded during maintenance. Results: The present study included 45 patients. The clinical signs present at inclusion were mostly cough (44.44%), asthenia (42.22%), headache (40%), and anosmia (35.55%). Dyspnoea and chest pain were less represented in 05 (11.11%) and 06 (13.33%) patients. Cough, dyspnoea, chest pain, fever, sore throat, headache, and nasal obstruction present at inclusion disappeared before Day 4 of treatment. Anosmia and asthenia disappeared before Day 7. At the inclusion visit (Day 1), CRP, WBC, and blood glucose were abnormal in 15 (33.33%), 13 (28.89%), and 11 (24.44%) patients respectively. In addition, 3 (6.66%) patients had elevated creatinine levels. Transaminases Alanine aminotransferase (ALAT) were elevated in 05 (11.11%) patients while Aspartate aminotransferase (ASAT) was elevated in 04 (8.89%) patients. After 4 days of treatment, the cure rate was 33.33% of patients and 48.89% after 7 days. The cumulative cure rate was 86.67% after 14 days of treatment. Conclusion: No serious side effects or allergic reactions were observed during treatment. No clinical complications were observed and all symptoms present resolved on the 7th day of treatment.

APIVIRINE, COVID-19, Clinical Study, Safety

Ouédraogo, D. , Tarnagda, G. , Ouédraogo, J. , Héma, A. , Tiendrebéogo, S. , Ouédraogo, S. , Ouédraogo, G. , Belemnaba, L. , Ouédraogo, N. , Kini, F. , Tarnagda, Z. , Ouédraogo, M. and Ouédraogo, S. (2023) Clinical Evaluation of the Safety and Efficacy of the Phytomedicine APIVIRINE Based on Aqueous Extracts of Dichrostachys glomerata (Forssk.). Chiov. (D. cinerea) in COVID-19 Patients without Signs of Severity. International Journal of Clinical Medicine, 14, 302-318. doi: 10.4236/ijcm.2023.146026.